Navigation Links
Avoiding a cartography catastrophe
Date:2/4/2013

KNOXVILLE, TN Since the mid-nineteenth century, maps have helped elucidate the deadly mysteries of diseases like cholera and yellow fever. Yet today's global mapping of infectious diseases is considerably unreliable and may do little to inform the control of potential outbreaks, according to a new systematic mapping review of all clinically important infectious diseases known to humans.

Of the 355 infectious diseases assessed in the review, 174 showed a strong rationale for mapping and less than 5 percent of those have been mapped reliably. Unreliable mapping makes it difficult to fully understand the geographic scope and threat of disease and therefore make informed policy recommendations for managing it, write the authors of the study, which appears as open access on Feb. 4 in the journal Philosophical Transactions of the Royal Society B.

An online, open-access database, which accompanies the study, provides a quantitative scheme for evaluating the quality of data available for each infectious disease as well as specific mapping recommendations for each disease. Among the recommendations for improving disease cartography are the use of new crowdsourcing techniques to gather data, such as analyzing the content and frequency of Twitter messages about disease. Twitter feeds during the 2009 H1N1 flu outbreak, for example, predicted outbreaks sooner than traditional disease surveillance methods.

"We have shown that novel solutions exist to enable us to use up-to-date data and technology to rapidly improve our geographic knowledge of a wide range of clinically important pathogens," said Katherine Battle, one of the study's co-authors from the University of Oxford.

Unique to the review is the inclusion of how the basic reproduction rate, which is the primary epidemiological number used to determine the degree which a disease can spread through a population, might vary among pathogens.

"There is a clear need for better estimates of the potential growth of infectious diseases that allow spatial variations to be taken into consideration, and this paper is a wonderful contribution to help us meet this need," said Louis Gross, the director of the National Institute for Mathematical and Biological Synthesis, which sponsored a workshop in 2011 that produced the paper.


'/>"/>

Contact: Catherine Crawley
ccrawley@nimbios.org
865-974-9350
National Institute for Mathematical and Biological Synthesis (NIMBioS)
Source:Eurekalert  

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Avoiding a cartography catastrophe
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... 8, 2017 About Voice Recognition Biometrics Voice ... it against a stored voiceprint template. Acoustic features ... and tone are compared to distinguish between individual ... as most PCs already have a microphone and ... recognition biometrics are most likely to be deployed ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... March 23, 2017 Kineta, Inc., a ... novel therapies in immuno-oncology, today announced the discovery ... molecule compounds that activate interferon response factor 3 ... demonstrate immune-mediated tumor regression in a murine colon ... who demonstrated complete tumor regression to initial drug ...
(Date:3/23/2017)... According to a report by Transparency Market Research (TMR), ... the presence of a large pool of participants; however, only a ... Sigma-Aldrich, compete with each other in this market. With Proliant being ... of this market in 2016.  ... As of now, a large number of vendors are ...
(Date:3/23/2017)... , March 23, 2017 In ... four equities in the Biotech industry: Sangamo Therapeutics Inc. ... Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from ... their free report at: ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major research ... GSK to generate genetic sequence data from the 500,000 volunteer ... researchers to gain valuable insights to support advances in the ... and life threatening diseases. ... Genetic evidence has revolutionized scientific discovery ...
Breaking Biology Technology: